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Objectives: To determine the in vitro effects of unfractionated heparin, fractionated heparin and direct
thrombin inhibition on platelet–monocyte aggregation, and to establish the in vivo effects of unfractionated
heparin and direct thrombin inhibition on platelet–monocyte aggregates in patients scheduled for
percutaneous coronary intervention (PCI).
Design: Platelet–monocyte aggregates were assessed in whole blood from 18 healthy volunteers after the
addition of unfractionated heparin (1 U/ml), enoxaparin (0.8 U/ml) or lepirudin (5.6 g/ml), and in 28
patients scheduled for elective PCI before and after administration of 100 U/kg of unfractionated heparin
or 0.75 mg/kg bivalirudin. The influence of P-selectin-mediated platelet–monocyte aggregation was
assessed with specific blocking antibodies.
Results: Addition of unfractionated heparin in vitro was associated with a higher level of platelet–monocyte
aggregates than in controls (20.1 (1.9)% v 16.2 (1.6)%, respectively, p , 0.001). However, platelet–
monocyte aggregation was not affected by enoxaparin or lepirudin (16.9 (2.0)% and 17.0 (2.2)%,
respectively, NS). Intravenous unfractionated heparin in vivo also resulted in an increase in platelet–
monocyte aggregates (absolute D 7.1 (2.7)%, p , 0.01), whereas intravenous bivalirudin had no effect
(absolute D 21.5 (2.4)%, NS). The addition of P-selectin blockade abolished any increase in platelet–
monocyte aggregates associated with heparin.
Conclusions: In vitro and in vivo unfractionated heparin is associated with increased platelet–monocyte
aggregation through a P-selectin-dependent mechanism. These findings provide a potential explanation
for the superior cardiovascular outcomes associated with fractionated heparins and direct thrombin
inhibitors.
C
oronary thrombosis has a central role in the pathogen-
esis of acute coronary syndromes and the complications
of percutaneous coronary intervention (PCI).1
Thrombin is both a key component of the coagulation
cascade and a potent platelet agonist. Unfractionated heparin
has been a cornerstone of antithrombotic treatment for many
years. However, unfractionated heparin has important
limitations and newer antithrombotic agents, such as the
fractionated heparins and the direct thrombin inhibitors,
have recently been developed.
Circulating activated platelets bind to leucocytes, predomi-
nately monocytes, to form platelet–leucocyte aggregates.
Platelet–monocyte aggregates are a sensitive marker of
platelet activation and are raised in acute coronary syn-
dromes, after PCI and during coronary artery bypass
grafting.2–5 Recently, it has become clear that adhesion of
activated platelets to monocytes has important functional
consequences. Platelet–monocyte binding induces expression
of cytokines, chemokines, adhesion molecules and tissue
factor.6–10 Furthermore, platelet–monocyte aggregation pro-
motes monocyte adhesion to activated endothelium and
recruitment of monocytes to sites of arterial injury.11 12 Thus,
platelet–monocyte aggregation not only is a sensitive marker
of platelet activation but also has important proinflammatory
and prothrombotic consequences.
The effect of unfractionated heparin and the newer
anticoagulant drugs on platelet activation and platelet–
monocyte interactions has not been clearly defined. The
objectives of this study were to determine the effects of
unfractionated heparin, fractionated heparin (enoxaparin)
and direct thrombin inhibition (lepirudin) on platelet–
monocyte aggregation in vitro, and to investigate the effects
of unfractionated heparin and direct thrombin inhibition
(bivalirudin) on platelet–monocyte aggregates in vivo.
METHODS
Study population and blood sampling
In vitro healthy volunteer studies
Peripheral venous blood was obtained from 18 healthy
volunteers, aged between 20–35 years, who were taking no
drugs. Ethical approval was obtained from the local research
ethics committee and all participants provided written
informed consent. Blood was drawn by clean venepuncture
of a large antecubital vein with a 19 gauge needle and
anticoagulated with sodium citrate (final concentration
0.106 mmol/l, Sarstedt Monovette). Care was taken to ensure
a smooth blood draw and the minimal necessary tourniquet
pressure was used. All samples were processed within 5 min
of drawing blood. Blood samples from the 18 volunteers were
each incubated at room temperature for 15 min with
unfractionated heparin (1 U/ml), enoxaparin (0.8 U/ml) or
lepirudin (5.6 g/ml). Platelet–monocyte aggregates were then
immunolabelled and assessed as described below.
The in vitro concentrations of anticoagulants were calcu-
lated to reflect concentrations of heparin, enoxaparin and
lepirudin used in clinical practice. Once we had shown that
lepirudin did not affect platelet activation at 5.6 mg/ml or
56 mg/ml (data for 56 mg/ml not shown), lepirudin at the
higher concentration was used as baseline anticoagulation
for the later studies. Sodium citrate was not used to avoid the
associated calcium depletion and therefore allow assessment
of platelet monocyte interactions in a more physiologically
relevant environment.
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To determine whether P-selectin-mediated platelet–mono-
cyte adhesion was affected by unfractionated heparin, blood
was collected from eight healthy volunteers and antic-
oagulated with lepirudin (56 g/ml). Platelet surface expres-
sion of P-selectin and platelet–monocyte aggregates were
quantified by two-colour flow cytometric analysis in whole
blood alone and after the addition of unfractionated heparin
(1 U/ml). In addition, a function-blocking monoclonal anti-
body specific for CD62P (CLB-thromb/6, final concentration
10 g/ml) was added to whole blood 5 min before the addition
of unfractionated heparin (1 U/ml). After the addition of
unfractionated heparin, the samples were incubated at room
temperature for a further 15 min before immunolabelling.
In vivo patient study
Blood samples were obtained from 28 patients scheduled for
PCI and 14 patients undergoing diagnostic coronary angio-
graphy. Patients were aged between 50–80 years and all were
treated with aspirin. Exclusion criteria were treatment with
an anticoagulant within the preceding month, myocardial
infarction within the preceding three months, PCI or surgery
within the preceding three months, renal or hepatic impair-
ment, inflammatory disorders or malignancy. Ethical
approval was obtained from the local research ethics
committee and all patients provided written informed
consent.
Blood samples were obtained from the 28 patients
scheduled for elective PCI at baseline and 5 min after
administration of either 100 U/kg unfractionated heparin
(n = 14) or 0.75 mg/kg bivalirudin (n = 14). Bivalirudin
was chosen as the direct thrombin inhibitor for the in vivo
study, as its safety and efficacy during PCI have been
established. Two blood samples, 5 min apart, were also
obtained from 14 control subjects undergoing diagnostic
coronary angiography. No angiography or instrumentation of
the coronary arteries was performed between blood sampling.
All samples were immunolabelled within 5 min of sampling.
Platelet–monocyte aggregation was determined by two-
colour flow cytometric analysis as described below.
Antibodies and other reagents
All chemicals were obtained from Sigma Chemical Company
unless otherwise stated. Phycoerythrin-conjugated CD14
(Tuk-4, IgG2a), phycoerythrin-conjugated CD62P (TRAP1,
IgG1) and their appropriate isotype controls were obtained
from DakoCytomation (Buckinghamshire, UK). Fluorescein
isothiocyanate-conjugated CD42a (GRP-P, IgG1) and control
IgG1 were obtained from Serotec Ltd (Oxford, UK).
Function-blocking CD62P monoclonal antibody (CLB-
thromb/6, IgG1) was obtained from CLB (Amsterdam, The
Netherlands). FACS-Lyse was obtained from Becton-
Dickinson (Cowley, UK). Clinical grade unfractionated
heparin (Leo Laboratories, UK), enoxaparin (Clexane;
Rhoˆne-Poulenc Rorer), lepirudin (Refludan, Pharmion) and
bivalirudin (Angiox, Nycomed) were used in all studies.
Immunolabelling and flow cytometry
Platelet–monocyte aggregates were measured as previously
described.2 Briefly, 60 l aliquots of whole blood were
incubated with anti-CD14, anti-CD42a and isotype-matched
controls for 20 min at room temperature, before 500 l of
FACS-Lyse was added and 2500 cells were measured by flow
cytometry (EPICS XL; Beckman Coulter, High Wycombe,
UK). Monocytes were identified by their typical light
scattering and CD14 expression. Platelet–monocyte aggre-
gates were defined as monocytes positive for CD42a. To
evaluate CD62P on platelets, blood was diluted 1:10 with
phosphate-buffered saline and incubated with anti-CD42a,
anti-CD62 and isotype-matched controls for 20 min at room
temperature before further diluting the cells 1:30 with 1%
paraformaldehyde. Platelets were identified by gating for
CD42a and 5000 cells were measured. All results are
expressed as percentage of positive cells. Data were analysed
with EXPO 32 software (Beckman Coulter).
Statistical analysis
Continuous variables are reported as mean (SEM). Data were
statistically analysed with Student’s t test or one-way
analysis of variance where appropriate. All calculations were
done with GraphPad Prism (V.3.02; Graph Pad Software, San
Diego, California, USA). Significance was taken at 5%.
RESULTS
Effect of in vitro addition of anticoagulants on
platelet–monocyte binding
Addition of unfractionated heparin (1 U/ml) in vitro was
associated with a higher level of platelet–monocyte aggre-
gates than in controls (20.1 (1.9)% v 16.2 (1.6)%, p , 0.001).
However, platelet–monocyte aggregation was not affected by
the addition of enoxaparin or lepirudin (16.9 (2.0)% and 17.0
(2.2)%, respectively, NS) (fig 1).
Mechanism of increased platelet–monocyte binding
Platelet surface expression of P-selectin was increased in
whole blood treated with unfractionated heparin (6.9 (1.2)%
v 3.2 (0.5)%, p , 0.01) (fig 2). Addition of P-selectin-
blocking antibodies (CLB-thromb/6, 10 g/ml) reduced plate-
let–monocyte aggregates by 71% (7.0 (1.2)% v 24.0 (2.6)%,
p , 0.001). The addition of unfractionated heparin after P-
selectin blockade was not associated with an increase in
25
20
10
15
5
0
LepirudinEnoxaparinUFHControl%
 P
la
te
le
t-m
on
oc
yt
e 
ag
gr
eg
at
es
Figure 1 Effect of unfractionated heparin (UFH), enoxaparin and
lepirudin on platelet–monocyte aggregates in vitro. Data are presented
as mean (SEM). *p , 0.001 versus control, enoxaparin or lepirudin.
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Figure 2 Effect of unfractionated heparin (UFH) on platelet surface P-
selectin expression in vitro. Data are presented as mean (SEM).
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platelet–monocyte aggregates (6.4 (1.5)% v 7.0 (1.2)%, NS)
(fig 3).
Effect of in vivo unfractionated heparin and direct
thrombin inhibition on platelet–monocyte binding
To confirm our in vitro findings, we evaluated platelet–
monocyte binding before and after giving unfractionated
heparin and bivalirudin to patients scheduled for PCI and in a
control group undergoing diagnostic coronary angiography
with no anticoagulation. Platelet–monocyte aggregation did
not differ at baseline between the three groups (mean 20.3
(1.7)%, p = 0.3). Consistent with our previous findings, in
vivo administration of unfractionated heparin at routine
clinical doses resulted in an increase in platelet–monocyte
aggregates (absolute D 7.1 (2.7)%, p , 0.01). Platelet–
monocyte binding did not change between the baseline and
5 min samples from patients receiving bivalirudin (absolute
D 21.5 (2.4)%, p = 0.6) or the control group (absolute D 0.6
(0.7)%, p = 0.4) (fig 4).
DISCUSSION
We have shown that in vitro and in vivo unfractionated
heparin is associated with platelet activation and an increase
in platelet–monocyte aggregates through a P-selectin-depen-
dent mechanism. This was not evident with direct thrombin
inhibition or with fractionated heparin. These prothrombotic
and proinflammatory effects of unfractionated heparin
provide a potential explanation for the superior cardiovas-
cular outcomes associated with fractionated heparins and
direct thrombin inhibitors.
Platelet activation is pivotal in the pathogenesis of acute
coronary syndromes and the complications of PCI and is
associated with adverse outcomes.13 14 Some previous studies
have suggested that use of unfractionated heparin may be
associated with platelet activation.15–17 Consistent with these
findings, our results showed that at therapeutic concentra-
tions, unfractionated heparin increased platelet surface
expression of P-selectin and platelet–monocyte aggregates,
both of which are considered to be sensitive markers of
platelet activation. In contrast, neither enoxaparin nor
lepirudin increased platelet–monocyte aggregates in vitro,
and the administration of bivalirudin in vivo did not affect
platelet–monocyte aggregation.
The mechanism by which unfractionated heparin causes
platelet activation in the absence of heparin-induced throm-
bocytopenia is uncertain. However, previous studies have
shown that unfractionated heparin can bind to a wide range
of receptors including the aIIbb3 integrin (glycoprotein IIb/
IIIa receptor), which in turn can result in outside-in
signalling.18 19 This probably triggers a series of intracellular
events leading to increased platelet activation.
Thrombosis and inflammation are closely related patho-
physiological processes involving platelets, leucocytes and
endothelial cells. Recently it has been appreciated that
extensive cross talk occurs between these cells. Adhesion of
activated platelets to monocytes induces nuclear transloca-
tion of nuclear factor-kB, the synthesis and expression of
interleukin 1b, interleukin 8, monocyte chemoattractant
protein 1, Mac-1, tissue factor and platelet-activating factor,
and superoxide generation.6–10 Platelet–monocyte conjugation
has been shown to promote monocyte adhesion to endothe-
lium and recruitment to sites of arterial injury.11 12
Furthermore, Manka and colleagues20 reported that the
absence of platelet P-selectin in apolipoprotein E-deficient
mice significantly attenuated macrophage recruitment and
neointimal formation after arterial injury. Thus, our findings
suggest that unfractionated heparin, but not enoxaparin or
direct thrombin inhibition, promotes platelet activation and
platelet–monocyte interactions with proinflammatory and
prothrombotic consequences. These findings may provide a
mechanistic explanation for the trials showing that enox-
aparin and direct thrombin inhibitors are superior to
unfractionated heparin for the prevention of ischaemic
events in patients presenting with acute coronary syndromes
or those undergoing PCI.21–25
Heparin binds to a large number of proteins of differing
structure and functionality.26 Previous in vitro studies have
suggested that unfractionated heparin may modulate leuco-
cyte function and exert an anti-inflammatory effect by
binding to and blocking adhesion molecules including P-
selectin, L-selectin and the integrin Mac-1 (CD11b/CD18).27–29
We have previously reported that platelet–monocyte con-
jugation is largely mediated by P-selectin expressed on the
surface of activated platelets binding to the constitutively
expressed monocyte receptor P-selectin glycoprotein ligand
1.2 Others have suggested that Mac-1 may also have an
important role in platelet–leucocyte adhesion.30 Therefore, if
unfractionated heparin effectively blocked P-selectin along
with other adhesion molecules, one would expect a pro-
nounced reduction in platelet–monocyte adhesion. In con-
trast, we found that treatment with unfractionated heparin
increased platelet–monocyte binding both in vitro and in
vivo. Furthermore, we found that P-selectin blockade
reduced baseline platelet–monocyte aggregation by 71% and
abolished any increase in platelet–monocyte binding after the
addition of unfractionated heparin. Thus, our results suggest
that unfractionated heparin does not inhibit P-selectin-based
cell adhesion but rather promotes increased P-selectin-
mediated adhesion between platelets and monocytes.
40
20
30
10
0
Anti-PS
+ UFH
Anti-PSUFHControl%
 P
la
te
le
t-m
on
oc
yt
e 
ag
gr
eg
at
es
Figure 3 Effect of unfractionated heparin (UFH) on platelet–monocyte
aggregates with and without P-selectin (PS) blockade by anti-CD62P
monoclonal antibody CLB-thromb/6 (final concentration 10 mg/ml).
Data are presented as mean (SEM). *p , 0.05 versus controls;
**p , 0.001 versus controls.
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Figure 4 Absolute change in platelet–monocyte aggregates after the
administration of 100 U/kg of unfractionated heparin or 0.75 mg/kg of
bivalirudin to patients scheduled for percutaneous coronary intervention
and in a control population undergoing diagnostic coronary
angiography with no anticoagulation. Data are presented as mean
absolute change (SEM) from baseline. *p , 0.01 versus baseline.
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Conclusions
We have shown that platelet–monocyte aggregation is
augmented in whole blood exposed to unfractionated heparin
through a P-selectin-dependent mechanism. This was not
evident in whole blood treated with enoxaparin or lepirudin,
or in vivo after the administration of bivalirudin. Thus,
unfractionated heparin not only activates platelets but also
increases the adhesion of platelets to peripheral blood
monocytes, with potential proinflammatory and prothrom-
botic consequences. Our findings provide a mechanistic
explanation for the superiority of fractionated heparins and
direct thrombin inhibitors over unfractionated heparin in
patients with acute coronary syndromes or those undergoing
PCI.
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